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Survivors of childhood brain tumors or other acquired brain injury (ABI) are at risk of poor health-related 
quality of life (HRQoL); its valid and reliable assessment is essential to evaluate the effect of their illness 
on their lives. The aim of this review was to critically appraise psychometric properties of patient-
reported outcome measures (PROMs) of HRQoL for these children, to be able to make informed 
decisions around selection of the most suitable PROM for use in clinical practice. 
Methods 
We searched MEDLINE, EMBASE, and PsycINFO for studies evaluating measurement properties of 
HRQoL PROMs in children treated for brain tumors or other ABI. Methodological quality of relevant 
studies was evaluated using the COSMIN checklist.   
Results 
Eight papers reported measurement properties of four questionnaires: Health Utilities Index (HUI), 
PedsQL Core and Brain Tumor Modules, and Child and Family Follow-up Survey (CFFS). Only the 
CFFS had evidence of content and structural validity. It also demonstrated good internal consistency 
whereas both PedsQL modules had conflicting evidence regarding this. Conflicting evidence regarding 
test-retest reliability was reported for HUI and PedsQL Core Module only. Evidence of measurement 
error/precision was favorable for HUI and CFFS and absent for both PedsQL modules. All four PROMs 
had some evidence of construct validity/hypothesis testing but no evidence of responsiveness to change.           
Conclusions 
Valid and reliable assessment is essential to evaluate impact of ABI on young lives. However, 
measurement properties of PROMs evaluating HRQoL appropriate for this population require further 
evaluation, specifically construct validity, internal consistency, and responsiveness to change.  
 





One child in every 600 will develop some form of cancer by 16 years of age1 and around 20% to 27% of 
these children will have a brain tumor2. Currently, 65.4% of children diagnosed with a brain tumor in 
Europe from 1999-2007 are reported to survive 5 or more years from diagnosis3 and the majority should 
have prolonged survival and become adults.  They often have multiple impairments and reduced health-
related quality of life (HRQoL)4-8. Approximately 62% will be left with a life-altering long-term 
disability9 comparable to the life-changing sequelae of severe traumatic or other acquired childhood brain 
injuries (ABI). ABI is post-natal injury to the brain that is sudden in onset and may be the result of head 
trauma or non-traumatic, following meningitis, stroke, metabolic derangement, sickle cell disease, or a 
brain tumor.   
In children aged less than 16 years, the incidence of hospitalization for traumatic brain injury 
(TBI) has been reported to be between 280 and 500 per 100,000. This implies that the total number of 
children admitted to hospital for TBI per annum in the UK is at least 35,000. Of these, about 2,000 (5.7%) 
will have severe TBI, 3,000 (8.6%) moderate TBI, and 30,000 (85.7%) mild TBI. In addition, the total 
number of children who sustain non-traumatic coma associated with severe or moderate encephalopathy 
is around 4,000 per year10. Also, the Central Brain Tumor Registry of the United States reported an 
incidence rate of newly diagnosed cases of brain tumor in children to be 5.54 per 100,000, equating to 
4,500 new cases annually11 and the overall annual incidence of childhood stroke has been estimated to be 
around 1.2 to 13 cases per 100,000 children under the age of 18 years12.   
In the context of delivery of clinical care, doctors vary in their ability to explore, elicit, and 
respond to information about HRQoL13 and discussion of the emotional, social, and cognitive issues 
impacting HRQoL after ABI or childhood cancer does not routinely take place in clinic consultations14. In 
addition, children and parents are often reluctant to raise psychosocial issues at clinic appointments15,16 
which they perceive to be more focused on medical issues such as monitoring tumor status and its 




PROMs measure a patient’s health status or health-related quality of life at a single point in time, 
and are collected through short, self-completed questionnaires17 without any third party acting as an 
intermediary. In the context of clinical research, the use of PROMs, including those assessing HRQoL, 
has proved to be a practicable means of assessing quality of survival in multicenter treatment trials18,19. 
Individualized use of PROMs in the routine care of children with a long-term illness has the potential to 
add valuable information about the impact of the disease, inform treatment planning, provide clinicians 
with timely information about a patient’s functional and emotional status and wellbeing20, and enhance 
family-clinician communication21. This helps clinical staff to deliver care focused on the needs and 
choices of each individual child and family22. Such use of PROMs has been evaluated in large groups of 
typically developing children, adolescents and adults and in adult patients with cancer23 and children with 
other long-term conditions24-27 but not in child/adolescent survivors of brain tumor or other ABI.  
When selecting PROMs for a specific purpose, it is necessary to examine how robust (valid and 
reliable) is the measurement of HRQoL produced by such questionnaires. A number of methodological 
approaches are available to determine aspects of reliability and validity28. The aim of the present 
systematic review was to critically appraise the psychometric properties of patient-reported outcome 
measures (PROMs) of HRQoL for these children, in order to be able to make informed decisions around 
selection of the most suitable PROM for use in clinical practice. 
Materials and Methods 
Systematic Review 
We undertook a systematic review of published evidence relating to the measurement properties of 
PROMs in children with brain tumors and other ABI and the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement29. A protocol was written which specified, a priori, the 
inclusion criteria and methods to be used. We also used methods recommended for appraising 
measurement properties and for assessing the methodological quality of papers that evaluate PROMs30, 
including the consensus-based standards for the selection of health status measurement instruments 





The search strategy was designed by an experienced information specialist (see acknowledgements) in 
discussion with topic experts (KB, CK, and CM) and an experienced systematic reviewer (JS). Blocks of 
search terms were combined including variants of ‘brain tumor/acquired brain injury’, ‘child/adolescent’, 
‘patient reported outcome measure’, ‘psychometric’ and the titles of generic PROMs suitable for use in all 
children or in all children with long-term health conditions, as listed in the most recent systematic review 
focusing on HRQoL in children with disabilities32.  
MEDLINE, EMBASE, and PsycINFO were searched for studies published from 1992 onwards in 
peer-reviewed journals whose purpose was to evaluate measurement properties of PROMs. An example 
from MEDLINE of this search strategy is shown in Appendix 1.  The electronic searches were completed 
on 7th February 2017 and updated on 28th May 2019. Publication details were uploaded into an Endnote 
reference management database and duplicates removed. Backwards citation chasing (one generation) 
from the reference lists of included papers was conducted by CM.  Forwards citation chasing for each 
included study using all databases in the Web of Science cited reference search resource was conducted 
by SH.   
Inclusion and exclusion criteria  
We sought published papers reporting evaluations of the measurement properties of multi-dimensional 
child (aged 5 to 18 years) self-report and/or parent-proxy report PROMs assessing health and wellbeing in 
children receiving care either for a brain tumor or other ABI of any kind (rather than for specific types of 
brain tumors or ABI). Evaluation of an English language version of the PROM was a requirement for 
inclusion. Studies in which only part of the sample were eligible for review were included only if 
psychometric analyses had been conducted on the eligible sub-groups within the sample.  Instruments 
administered by an interviewer and single domain-specific questionnaires (e.g. to assess only depression, 





An inclusion/exclusion criteria decision chart was used to aid the selection of articles likely to yield 
relevant results from their titles and abstracts.  The use of this chart was piloted by SH and KB who 
screened the first 10 articles together to test agreement over inclusion of articles. All remaining titles and 
abstracts were screened in batches of 40 by SH and, independently, by KB.  The evaluations of each batch 
of 40 by the two reviewers were then compared and any disagreements discussed and resolved.  Full texts 
were then retrieved from this list of potential studies by SH.  KB then checked the list of included and 
excluded studies to confirm agreement. Disagreements were discussed and resolved between the 
reviewers.   
Data extraction, appraisal, and synthesis of included studies 
Descriptive characteristics of included studies and measurement properties of the PROMs were extracted 
by SH. These extracted data were checked by KB and the final extracted data set was agreed in discussion 
with CM. The criteria of Fitzpatrick et al. (1998)33 were adopted for evaluation of the patient-based 
outcome measures within the extracted data set.    
The COSMIN Risk of Bias checklist of Consensus-based standards for the selection of health 
status measurement instruments (COSMIN) was used to assess the methodological quality of the included 
studies.  The checklist is comprised of 12 boxes which together cover three domains: content validity, 
internal structure, and remaining measurement properties – namely reliability, measurement error, 
criterion validity, hypothesis testing for construct validity, and responsiveness to change31. Ten of the 12 
boxes can be used to assess whether a study meets standards for good methodological quality and 9 of 
them contain standards for the included measurement properties. These are each scored on a four-point 
rating scale of the way in which each measurement property was assessed.  
All of the above properties were assessed (Table 1) excepting cross-cultural validity which was 
not relevant as our search only included English language reports.  Criterion validity was not applicable 
as in the case of HRQoL there is no criterion against which HRQoL measures can be judged (except for 




An overall score for the methodological quality of a study was determined by CM for each 
measurement property separately as a single rating34, arrived at by taking the lowest rating of any of the 
items in a box35. The review team then considered the evidence for each PROM and summarized in a 
single rating for each measurement property following methods commonly used for presentation of 
findings against the COSMIN criteria (Table 2). From these ratings conclusions were drawn on the extent 
to which each PROM could be considered robust for measuring HRQoL in children treated for brain 
tumors or other ABI.  
 
Table 1 about here.  
 
Table 2 about here 
 
Results 
The electronic searches resulted in 472 articles after the removal of duplicates. Of these, 374 were 
excluded leaving 98 potentially relevant studies whose full text articles were retrieved. Screening of these 
led to the exclusion of a further 90 papers leaving eight studies remaining for evaluation (Fig. 1). 
Backwards citation chasing identified two potentially relevant papers and forward citation chasing 
identified six potentially relevant papers, all of which were subsequently excluded due to inappropriate 
population (n=4), inappropriate instrument (n=3), or lack of relevant data (n=1). 
Four self-report and/or parent-proxy report PROMs – the Health Utilities Index (HUI), the 
Pediatric Quality of Life Inventory Core Module (PedsQL), the PedsQL Brain Tumor Module, and the 
Child and Family Follow-Up Survey (CFFS) - were evaluated and appraised in the eight included studies 
(Tables 3&4) and these are briefly described here.  
The HUI and PedsQL are generic measures of HRQoL whereas the PedsQL Brain Tumor Module 
and the CFFS are disease-specific. The HUI is a rating scale used to measure general health status with 




of the quality-adjusted life years (QALY) calculation used in population health and economics. Answers 
to 15 questions about health state, scored at 3 to 6 health status levels, can be grouped in two different 
ways to produce  either HUI2 or HUI3 scores across 7 or 8 ‘attributes’ of health. HUI3, for example, 
groups health status levels to create attribute scores for Vision, Hearing, Speech, Ambulation, Dexterity, 
Emotion, Cognition, and Pain.  
The PedsQL is a measure of HRQoL with 23 questions across four core scales: Physical, 
Emotional, Social, and School.  The 24-item PedsQL Brain Tumor Module was designed to measure 
HRQoL in children undergoing treatment for a brain tumor. The questions are divided between six 
subscales: Cognitive problems, pain and hurt, movement and balance, procedural anxiety, nausea, and 
worry.  
The CFFS was developed as a parent report measure to monitor needs and outcomes of children 
and youth with acquired brain injury and their families. It consists of five sections with a total of 71 
closed or open-ended questions. Section 1 asks about the child’s physical and emotional health and well-
being, primary way of moving around and communicating, and medical problems or hospitalizations 
within the last year or since leaving the rehabilitation program. Section 2 includes the Child and 
Adolescent Scale of Participation (CASP) and three subsequent open-ended questions about equipment, 
modifications or strategies that are used to promote the child’s participation. Section 3 includes the Child 
and Adolescent Factors Inventory (CAFI) and Child and Adolescent Scale of Environment (CASE) and a 
question about health or medical restrictions on the child’s daily activities. Section 4 enquires about the 
child’s current educational placement, rehabilitation and health services, satisfaction with services, the 
family’s quality of life, and current services and needs. Finally, Section 5 seeks suggestions to improve 
services at the program from where the child was discharged to better address the needs of the child and 
family and additional information that was not addressed in the CFFS.  
Completion time for the HUI and the PedsQL (core or brain tumor module) is about 5 minutes 




modules and from 12 years old for the HUI while the CFFS is available as parent-report only (Table 4). 
None of the studies had assessed all psychometric properties of the PROM in question.   
Content validity: this had been assessed only for the CFFS and in this case the evidence for its validity 
was good. 
Internal structure: only the CFFS had been assessed for evidence of structural validity and there was 
good evidence that it possessed this property. Internal consistency had been evaluated for the CFFS (good 
evidence) and for the PedsQL Core and PedsQL Brain Tumor Modules (equivocal evidence) but not for 
the HUI (Supplementary Table S1and Table 5).  
Other measurement properties: evidence for test/re-test reliability and proxy reliability was available 
but conflicting for the HUI and PedsQL Core module and absent for the PedsQL Brain Tumor module 
and the CFFS. Favorable evidence of precision was available for the HUI but absent for the PedsQL Core 
and Brain Tumor Modules or the CFFS. Favorable evidence of hypothesis testing/construct validity was 
available for all measures. There was no evidence of responsiveness to change over time for any of the 
PROMs.  
The methodological quality of the included studies varied from adequate to very good 
(Supplementary Table S2).  The CFFS had had the most measurement properties evaluated and these 
studies were of high quality (Supplementary Table S2).   
 
Table 3 about here 
Table 4 about here 
Table 5 about here 
Discussion  
This is the first systematic review of evaluations of the psychometric properties of PROMs in survivors of 




PROMs with relevant information about their measurement properties in children treated for brain tumors 
or ABI. Some evidence in favor of each instrument was found with respect to those properties that had 
been examined but caution is needed with respect to those properties that have not been evaluated: 
notably content and structural validity for the HUI and the PedsQL; test/retest reliability and precision / 
measurement error for the PedsQL; and responsiveness to change over time for all measures. In contrast 
to the HUI and the CFFS, the self-report versions of the two PedsQL modules had been specifically 
designed for the pediatric age group.  
The PedsQL Core Module has previously been reported, in the setting of orthopedic, and 
rheumatology clinics, to be sensitive to increasing disease severity, responsive to clinical change over 
time, and to demonstrate impact on clinical decision-making resulting in increases in HRQoL36. The 
developer of the PedsQL has recommended it as a screening instrument to use in conjunction with 
disease-specific modules to target symptoms for interventions37. 
Our strict selection criteria did not reveal any longitudinal/follow-up studies in which 
responsiveness to change may have been assessed incidentally but the present study does not rule out their 
existence. Assessing the size of meaningful change above measurement error of the scores from PROMs 
is desperately needed from further research. It therefore behoves the user to design validation steps when 
adopting one of the questionnaires for clinical or research use to plug this evidence gap, for example 
when interpreting studies that have used these questionnaires to measure change.   
The validity of the use of a PROM to communicate with families and better focus their care to 
improve their HRQoL depends on the method by which it was developed. This method of development of 
a PROM is to an extent separate from its measurement properties although may be reflected in measures 
of content validity. These methods have been highly variable and are often not clearly specified. Thus, 
there would be merit in discussing further with survivors of brain tumor or other ABI and their caregivers 
the salience and relevance of the individual questions within questionnaires and relying on responses to 
individual questions rather than questionnaire scores as a means to enhance communication between care-




childhood would also help to identify whether or not there is a need to develop a condition-specific 
PROM for use in child and adult survivors of brain tumor or other ABI in childhood.  
Two systematic reviews of HRQoL measures in children with long-term conditions other than 
ABI seem to have particular relevance to selection for use in child survivors of brain tumors or other ABI. 
The first conducted was a systematic review of the psychometric properties of measures for use in 
children with neurodisability32,38. It found evidence relating to measurement properties of seven generic 
PROMs (The Child Health and Illness Profile, The Child Health Questionnaire, the Child Quality of Life 
questionnaire, KIDSCREEN, the PedsQL, the Student Life Satisfaction Scales, and the Youth Quality of 
Life Instrument), two chronic-generic PROMs (the DISABKIDS and the Neurology Quality of Life 
Measurement System) and three preference-based measures (HUI, the EQ-5D-Y, and the Comprehensive 
Health Status Classification system – Preschool).  In the instance of preference-based measures, they 
noted a dearth of evidence of face, content, and construct validity, or test-retest reliability and for all 
measures, a lack of evidence for responsiveness and measurement error. 
The second systematic review was of PROMs of ‘cancer-specific’ HRQoL measures for use in 
children with cancer and identified nine measures for proxy completion, of which six had parallel 
measures for self-completion by children39. This review did not consider generic scales that had been 
applied in children with cancer (e.g. the PedsQL Core Module) but did note that the MMQL-UK child 
and parent versions have been validated as generic measures of QoL that can be used with healthy 
children and those with chronic conditions other than cancer. Adequate detail about how questionnaire 
items were generated from qualitative interviews was provided for only four questionnaires and most did 
not combine this with literature review or expert opinion. Some questionnaires required further 
psychometric evaluation before they could be recommended leaving just five recommendable measures: 
the Miami Pediatric Quality of Life Questionnaire (MPQS), the Minneapolis-Manchester Quality of Life 
Instrument (MMQL), the PedsQL Cancer Module, the Pediatric Functional Assessment of Cancer 
Therapy-Childhood: Brain Tumor Survivor (PFACT-BT), and the Pediatric Oncology Quality of Life 




for a brain tumor or other ABI but, with the exception of the PFACT-BT, their measurement properties 
and performance have not been evaluated in either of these groups. The PFACT-BT is administered by an 
interviewer. This was an exclusion criterion for the present review and unfortunately also greatly limits 
the applicability of this measure.  
Advantages of self-administered questionnaires include the reduction in burden associated with 
respondents of being able to answer at their own convenience and in their own time, the obviation of any 
need for a trained administrator, and, when done on line, the avoidance of transcription errors and greater 
efficiency and of data being entered at the moment that it is self-administered.  However, the development 
of the questionnaires needs to be robust since measurement error may be made more likely by the absence 
of a trained administrator, if questions are poorly worded or formatted. 
However, other considerations relating to the constraints of health care systems, including time 
and resources, need to be taken into account. Not all the PROMs we identified are suitable for systematic 
use in an outpatient clinical health care setting. PROMs with costly licensing fees are not feasible to use 
in public health care systems where funds are limited. Also PROMs which are lengthy to discuss will not 
be adopted due to clinical time constraints. PROMs also need to be relevant and suitable for follow-up 
consultations after treatment has ended. The CFFS appears to be the most thoroughly developed and 
comprehensive measure in this population but it is lengthy, at 71 questions, and the absence of any self-
report version is a limitation of its use as a measure of quality of life. For these reasons, the PedsQL – 
Core Module, which is being widely used in childhood cancer research, may be the most suitable PROM 
for use in a clinical setting, notwithstanding the gaps in evidence regarding some of its psychometric 
properties.  
Strengths of the present review include a comprehensive and systematic search strategy, use of 
standard criteria for the evaluation of the measurement properties of each PROM, and use of defined 
criteria to measure the quality of the studies that had been undertaken to assess these properties in 
participants with brain tumors or acquired brain injury in childhood. Synthesis of the findings of this 




strength. The restriction of the systematic review to evaluations of questionnaires in the English language 
is both a limitation of this study, in that it restricts its relevance to English speaking service users, and a 
strength in that issues of cross-cultural validity apply to a much smaller extent than would be the case for 
an evaluation of instruments in more than one language40.  
In summary, both the present systematic review of measurement properties of PROMs when used 
in child survivors of brain tumors or other ABI and the preceding systematic reviews of PROMs when 
used in survivors of childhood cancer and in children with neurodisability indicate lack of evidence 
regarding measurement error or responsiveness to change and, in the case of preference-based measures, 
lack of evidence of content or construct validity, or test-retest reliability. Factors contributing to this lack 
of evidence may include the assumption by investigators that psychometric properties shown in healthy 
populations also apply to survivors of brain tumors, difficulty of accessing study populations of sufficient 
size to reach reliable conclusions about the validity of measures used, and/or limited awareness of 
investigators about the importance of validating psychometric properties of those measures. 
To conclude, the four PROMs that were identified in our systematic review and a handful of other 
PROMs identified in previous systematic reviews of child survivors of non-CNS cancers and of children 
with neuro-disability had some evidence of favorable measurement properties but this was limited and 
insufficient to enable selection of PROMs suitable for use in survivors of childhood brain tumors or other 
ABI, particularly for the measurement of change. For communication about HRQoL, the paucity of 
evidence of content validity in these groups suggests the need for further discussion with these patient 
groups to inform selection of questions that address their concerns and we are, to that end, currently 
engaged in a qualitative study of the expressed views of brain tumor survivors. In the meantime there is 
clearly a need for studies that evaluate the measurement properties of those generic PROMs of HRQoL 
when used in these patients whether the purpose is to inform the care of individuals or to describe the 
HRQoL of groups of patients.  
Funding 





We would like to acknowledge the help of Karen Welch who conducted the systematic search on our 
behalf.  Also thanks goes to Sasja Schepers who commented on a draft of the systematic review protocol 








1. Stiller CA. Childhood cancer in Britain: Incidence, survival, mortality. Oxford: Oxford University Press; 
2007. 
2. Baade PD, Youlden DR, Valery PC, et al. Trends in incidence of childhood cancer in Australia, 1983-
2006. Br J Cancer 2010;102(3):620-626. 
3. Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-
5--a population-based study. Lancet Oncol 2014;15(1):35-47. 
4. Packer RJ, Gurney JG, Punyko JA, et al. Long-term neurologic and neurosensory sequelae in adult 
survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol 
2003;21(17):3255-3261. 
5. Boman KK, Hoven E, Anclair M, et al. Health and persistent functional late effects in adult survivors of 
childhood CNS tumours: a population-based cohort study. Eur J Cancer 2009;45(14):2552-2561. 
6. Cardarelli C, Cereda C, Masiero L, et al. Evaluation of health status and health-related quality of life in 
a cohort of Italian children following treatment for a primary brain tumor. Pediatr Blood Cancer 
2006;46(5):637-644. 
7. Boman KK, Lindblad F, Hjern A. Long-term outcomes of childhood cancer survivors in Sweden: A 
population-based study of education, employment, and income. Cancer 2010;116(5):1385-1391. 
8. Bull KS, Liossi C, Culliford D, et al. Child-related characteristics predicting subsequent health-related 
quality of life in 8- to 14-year-old children with and without cerebellar tumors: a prospective 
longitudinal study. Neuro-Oncol Pract 2014;1(3):114-122. 
9. Macedoni-Luksic M, Jereb B, Todorovski L. Long-term sequelae in children treated for brain tumors: 




10. NHS England. 2013/14 NHS standard contract for paediatric neurorehabilitation. 
https://www.england.nhs.uk/wp-content/uploads/2018/09/Paediatric-Neurorehabilitation.pdf. 
Accessed May 5, 2019 
11. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and other central 
nervous system tumors diagnosed in the United States in 2010-2014. Neuro-Oncol 2017;19:V1-
V88. 
12. Tsze DS, Valente JH. Pediatric stroke: a review. Emerg Med Int 2011;2011:734506. 
13. NICE. Children and young people cancer survivorship initiative: Improving quality and the patient 
experience. 
http://www.nice.org.uk/savingsAndProductivityAndLocalPracticeResource?ci=http%3a%2f%2far
ms.evidence.nhs.uk%2fresources%2fQIPP%2f844812%3fniceorg%3dtrue. Accessed May 5, 2019. 
14. Engelen V, van Zwieten M, Koopman H, et al. The influence of patient reported outcomes on the 
discussion of psychosocial issues in children with cancer. Pediatr Blood Cancer 2012;59(1):161-
166. 
15. Sibelli A. Quality of Life following Treatment for a Brain Tumour:  child and parent perspectives. MSc. 
Southampton, 2011. 
16. King T. A Qualitative Exploration of Longitudinal Quality of Life and Illness Experience in Childhood 
LGCA Brain Tumour Survivors: From a Child's Perspective. MSc. Southampton, 2012. 
17. . Patient Reported Outcome Measures (PROMs). https://www.england.nhs.uk/statistics/statistical-
work-areas/proms/. Accessed May 5, 2019. 
18. Bull KS, Spoudeas HA, Yadegarfar G, et al. Reduction of health status 7 years after addition of 
chemotherapy to craniospinal irradiation for medulloblastoma: A follow-up study in PNET 3 trial 




19. Limond JA, Bull KS, Calaminus G, et al. Quality of survival assessment in European childhood brain 
tumour trials, for children aged 5 years and over. Eur J Paediatr Neurol 2015;19(2):202-210. 
20. Santana MJ, Feeny D. Framework to assess the effects of using patient-reported outcome measures 
in chronic care management. Qual Life Res 2014;23(5):1505-1513. 
21. Ireland P, Horridge KA. The Health, Functioning and Wellbeing Summary Traffic Light Communication 
Tool: a survey of families' views. Dev Med Child Neurol 2017;59(6):661-664. 
22. NHS England. Putting Patients First: The NHS business plan for 2013/2014-2015/2016. 
http://www.england.nhs.uk/pp-1314-1516/. Accessed May 5, 2019. 
23. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves 
communication and patient well-being: A randomized controlled trial. J Clin Oncol 
2004;22(4):714-724. 
24. Tavernor L, Barron E, Rodgers J, et al. Finding out what matters: validity of quality of life 
measurement in young people with ASD. Child Care Health Dev 2013;39(4):592-601. 
25. Haverman L, van Rossum MA, van Veenendaal M, et al. Effectiveness of a web-based application to 
monitor health-related quality of life. Pediatr 2013;131(2):e533-543. 
26. Haverman L, Engelen V, van Rossum MA, et al. Monitoring health-related quality of life in paediatric 
practice: development of an innovative web-based application. BMC Pediatr 2011;11:3. 
27. Snyder CF. Using Patient-Reported Outcomes in Clinical Practice: A Promising Approach? J Clin Oncol 
2014;32(11):1099-+. 
28. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on 
taxonomy, terminology, and definitions of measurement properties for health-related patient-




29. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and 
meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. 
Brit Med J 2009;339. 
30. Dissemination CfRa. Systematic reviews: CRD's guidance for undertaking reviews in health care. 3rd 
ed. York, UK York Publishing Services Ltd.; 2009. 
31. Mokkink LB, de Vet HCW, Prinsen CAC, et al. COSMIN Risk of Bias checklist for systematic reviews of 
Patient-Reported Outcome Measures. Qual Life Res 2018;27(5):1171-1179. 
32. Janssens A, Rogers M, Gumm R, et al. Measurement properties of multidimensional patient-reported 
outcome measures in neurodisability: a systematic review of evaluation studies. Dev Med Child 
Neurol 2016;58(5):437-451. 
33. Fitzpatrick R, Davey C, Buxton MJ, et al. Evaluating patient-based outcome measures for use in 
clinical trials. Health Technol Assess 1998;2(14):i-iv,1-74. 
34. Uijen AA, Heinst CW, Schellevis FG, et al. Measurement Properties of Questionnaires Measuring 
Continuity of Care: A Systematic Review. PloS one 2012;7(7). 
35. Terwee CB, Mokkink LB, Knol DL, et al. Rating the methodological quality in systematic reviews of 
studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res 
2012;21(4):651-657. 
36. Varni JW, Seid M, Knight TS, et al. The PedsQL (TM) 4.0 Generic Core Scales: Sensitivity, 
responsiveness, and impact on clinical decision-making. J Beh Med 2002;25(2):175-193. 
37. Varni JW, Burwinkle TM, Seid M. The PedsQL as a pediatric patient-reported outcome: Reliability and 
validity of the PedsQL Measurement Model in 25,000 children. Expert Rev Pharmacoecon 




38. Janssens A, Rogers M, Coon JT, et al. A Systematic Review of Generic Multidimensional Patient-
Reported Outcome Measures for Children, Part II: Evaluation of Psychometric Performance of 
English-Language Versions in a General Population. Val Health 2015;18(2):334-345. 
39. Klassen AF, Strohm SJ, Maurice-Stam H, et al. Quality of life questionnaires for children with cancer 
and childhood cancer survivors: A review of the development of available measures. Support 
Care Cancer 2010;18(9):1207-1217. 
40. Wild D, Grove A, Martin M, et al. Principles of good practice for the translation and cultural 
adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR Task 
Force for Translation and Cultural Adaptation. Val Health 2005;8(2):94-104. 
41. Barr RD, Simpson T, Whitton A, et al. Health-related quality of life in survivors of tumours of the 
central nervous system in childhood - a preference-based approach to measurement in a cross-
sectional study. Euro J Cancer 1999;35(2):248-55. 
42. Glaser AW, Davies K, Walker D, et al. Influence of proxy respondents and mode of administration on 
health status assessment following central nervous system tumours in childhood. Qual Life Res 
1997;6(1):43-53. 
43. Glaser AW, Furlong W, Walker DA, et al. Applicability of the Health Utilities Index to a population of 
childhood survivors of central nervous system tumours in the U.K. Euro J Cancer 1999;35(2):256-
61. 
44. Bhat SR, Goodwin TL, Burwinkle TM, et al. Profile of daily life in children with brain tumors: An 
assessment of health-related quality of life. J Clin Oncol 2005;23(24):5493-500. 
45. Eiser C, Vance YH, Horne B, et al. The value of the PedsQLTM in assessing quality of life in survivors 
of childhood cancer. Child Care Health Dev 2003;29(2):95-102. 
46. Palmer SN, Meeske KA, Katz ER, et al. The PedsQL (TM) brain tumor module: Initial reliability and 




47. Bedell GM. Developing a follow-up survey focused on participation of children and youth with 
acquired brain injuries after discharge from inpatient rehabilitation. NeuroRehab 
2004;19(3):191-205. 
48. Bedell G. Further validation of the Child and Adolescent Scale of Participation (CASP). Dev 
Neurorehab 2009;12(5):342-351. 
49. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health 
status classification system. Health Utilities Index Mark 2. Med Care 1996;34(7):702-22. 
50. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the 
health utilities index mark 3 system. Med Care 2002;40(2):113-28. 
51. Varni JW, Seid M, Kurtin PS. PedsQL (TM) 4.0: Reliability and validity of the pediatric quality of life 






Figure 1. PRISMA flowchart for the identification and selection of studies evaluating psychometric 
properties of PROMs in children treated for brain tumors or acquired brain injury.  
PRISMA=Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PROMs=Patient-
reported outcome measures 
